サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1081113

癌研究用マウスモデルの世界市場：北米が世界市場の約半分のシェアを占める

Market Study on Oncology Mice Models: North America Accounts for Nearly Half Global Market Share
出版日: | 発行: Persistence Market Research | ページ情報: 英文 250 Pages | 納期: 2～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
癌研究用マウスモデルの世界市場：北米が世界市場の約半分のシェアを占める
出版日: 2022年04月13日
発行: Persistence Market Research
ページ情報: 英文 250 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の癌研究用マウスモデルの市場を調査し、市場概要、主要動向、市場成長への各種影響因子の分析、パイプラインの分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合分析、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 主要市場動向

  • 市場に影響を与える主な動向
  • 製品イノベーション/開発動向

第4章 主要成功要因

  • 癌治療薬：パイプライン分析
  • 癌免疫治療薬：パイプライン分析
  • 癌免疫治療薬の臨床試験を継続している製薬企業のリスト
  • 進行中の癌免疫治療薬の臨床試験に関与する学術・研究機関のリスト
  • 前臨床CROのリスト
  • 親市場の分析
  • 癌併用療法の臨床試験の相対数
  • 癌免疫治療薬の開発環境
  • 前臨床癌免疫治療薬モデルのリスト
  • 主要な規制シナリオ
  • ポーターの分析
  • PESTLE分析
  • サプライチェーン分析

第5章 市場の背景

  • マクロ経済的要因
  • 予測要因：関連性・影響
  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会分析

第6章 COVID-19の分析

  • 現在のCOVID-19統計・予想される将来の影響
  • 現在のGDP予測・予想される影響
  • 現在の経済予測・2008年の経済分析との比較
  • COVID-19・影響分析
  • 回復シナリオ：短期・中期・長期的影響

第7章 世界の癌研究用マウスモデル市場の需要分析・予測

  • 過去の市場分析
  • 現在および将来の市場予測

第8章 世界の癌研究用マウスモデル市場の分析・予測：製品別

  • イントロダクション/主な調査結果
  • 過去の分析
  • 現在および将来の予測
    • ヒト化免疫システムマウスモデル
    • 同系腫瘍マウスモデル
    • 免疫不全マウスモデル
    • NOGマウスモデル
    • 自然発生腫瘍マウスモデル
    • その他
  • 市場の魅力

第9章 世界の癌研究用マウスモデル市場の分析・予測：エンドユーザー別

  • イントロダクション/主な調査結果
  • 過去の分析
  • 現在および将来の予測
    • CRO
    • 製薬企業・バイオ製薬企業
    • 学術・研究機関
  • 市場の魅力

第10章 世界の癌研究用マウスモデル市場の分析・予測：地域別

  • イントロダクション/主な調査結果
  • 過去の分析
  • 現在および将来の予測
    • 北米
    • ラテンアメリカ
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
  • 市場の魅力

第11章 北米の癌研究用マウスモデル市場の分析・予測

第12章 ラテンアメリカの癌研究用マウスモデル市場の分析・予測

第13章 欧州の癌研究用マウスモデル市場の分析・予測

第14章 アジア太平洋の癌研究用マウスモデル市場の分析・予測

第15章 中東・アフリカの癌研究用マウスモデル市場の分析・予測

第16章 癌研究用マウスモデル市場の分析・予測：国別

  • 米国
  • カナダ
  • ブラジル
  • アルゼンチン
  • メキシコ
  • ドイツ
  • イタリア
  • フランス
  • 英国
  • スペイン
  • ベネルクス諸国
  • ロシア
  • 中国
  • 日本
  • インド
  • オーストラリア・ニュージーランド
  • GCC諸国
  • 南アフリカ

第17章 市場構造の分析

  • 市場分析：企業ティア別
  • 主要企業の市場シェア分析

第18章 競合分析

  • 競合ベンチマーク
  • 競合ダッシュボード
  • 競合ディープダイブ
    • The Jackson Laboratory
    • Taconic Biosciences
    • Charles River Laboratories
    • Shanghai Model Organisms Center Inc.
    • Envigo
    • Biocytogen
    • Genoway
    • Crown Bioscience Inc.(JSR Corporation).
    • Cyagen
    • Applied stem cells
    • Ingenious Targeting Laboratory
    • PolyGene-Transgenic mice model company
    • Creative Biolabs
    • TransCure Bioservices
    • Champions Oncology Inc
    • Certis Oncology
    • Signature
    • Pharmaron
    • Laboratory Corporation of America Holdings
    • Gempharmatech
    • Janvier Labs
    • Harbour BioMed

第19章 仮定・頭字語

第20章 調査手法

図表

List of Tables

  • Table 01: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
  • Table 02: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by End User
  • Table 03: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Region
  • Table 04: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
  • Table 05: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
  • Table 06: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
  • Table 07: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
  • Table 08: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
  • Table 09: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
  • Table 10: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
  • Table 11: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
  • Table 12: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
  • Table 13: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User

List of Figures

  • Figure 01: Global Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
  • Figure 02: Global Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
  • Figure 03: Global Oncology Mice Models Market Absolute $ Opportunity, 2022-2032
  • Figure 04: Global Oncology Mice Models Market Share Analysis (%) By Product, 2022 & 2032
  • Figure 05: Global Oncology Mice Models Market Y-o-Y Growth (%) By Product, 2022- 2032
  • Figure 06: Global Oncology Mice Models Market Attractiveness Analysis, By Product
  • Figure 07: Global Oncology Mice Models Market Share Analysis (%) By End User, 2022 & 2032
  • Figure 08: Global Oncology Mice Models Market Y-o-Y Growth (%) By End User, 2022-2032
  • Figure 09: Global Oncology Mice Models Market Attractiveness Analysis, By End User
  • Figure 10: Global Oncology Mice Models Market Share Analysis (%) By Region, 2022 & 2032
  • Figure 11: Global Oncology Mice Models Market Y-o-Y Growth (%) By Region, 2022-2032
  • Figure 12: Global Oncology Mice Models Market Attractiveness Analysis, By Region
  • Figure 13: North America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)
  • Figure 14: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
  • Figure 15: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
  • Figure 16: North America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
  • Figure 17: North America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
  • Figure 18: North America Oncology Mice Models Market Attractiveness Analysis, By Product
  • Figure 19: North America Oncology Mice Models Market Attractiveness Analysis, By End User
  • Figure 20: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)
  • Figure 21: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
  • Figure 22: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
  • Figure 23: Latin America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
  • Figure 24: Latin America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
  • Figure 25: Latin America Oncology Mice Models Market Attractiveness Analysis, By Product
  • Figure 26: Latin America Oncology Mice Models Market Attractiveness Analysis, By End User
  • Figure 27: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)
  • Figure 28: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
  • Figure 29: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
  • Figure 30: Europe Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
  • Figure 31: Europe Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
  • Figure 32: Europe Oncology Mice Models Market Attractiveness Analysis, By Product
  • Figure 33: Europe Oncology Mice Models Market Attractiveness Analysis, By End User
  • Figure 35: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
  • Figure 36: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
  • Figure 37: Asia Pacific Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
  • Figure 38: Asia Pacific Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
  • Figure 39: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By Product
  • Figure 40: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By End User
  • Figure 41: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)
  • Figure 42: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
  • Figure 43: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
  • Figure 44: Middle East and Africa (MEA) Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
  • Figure 45: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
  • Figure 46: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By Product
  • Figure 47: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By End User
  • Figure 48: U.S. Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 49: U.S. Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 50: Canada Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 51: Canada Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 52: Mexico Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 53: Mexico Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 54: Brazil Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 55: Brazil Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 56: India Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 57: India Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 58: China Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 59: China Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 60: Japan Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 61: Japan Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 62: Germany Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 63: Germany Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 64: France Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 65: France Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 66: Italy Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 67: Italy Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 68: Russia Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 69: Russia Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 70: GCC Countries Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 71: GCC Countries Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
  • Figure 72: South Africa Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
  • Figure 73: South Africa Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
目次
Product Code: PMRREP33046

Oncology Mice Models Market - Scope of Report

The latest publication by Persistence Market Research on the oncology mice models market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for oncology mice models and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the oncology mice models market. The insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the oncology mice models market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the oncology mice models market are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research's study on the oncology mice models market offers information divided into three important segments - product, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Product

Humanized Immune System Mice Models

Syngeneic Tumor Mice Models

Immunodeficient Mice Models

NOG Mice Models

Spontaneous Tumor Mice Models

Others

End User

Contract Research Organizations

Pharma and Biopharma Companies

Academic and Research Institutes

Region

North America

Latin America

Europe

Asia Pacific

Middle East and Africa (MEA)

Key Questions Answered in Report

Which regions will continue to remain the most profitable markets for oncology mice models over the coming years?

How will changing trends impact the market?

How has the COVID-19 crisis impacted market growth?

How can market players capture the low-hanging opportunities in developed regions?

What are the strategies of stakeholders in the market to shape their position in this landscape?

What are the restraining factors that investors need to be aware of and might tackle while investing in the market?

What are the developmental trends that will impact the market?

How can companies in the oncology mice models market avail themselves the growth opportunities in developed and emerging sectors?

Research Methodology

In Persistence Market Research's study, a unique research methodology is utilized to conduct extensive research on the growth of the oncology mice models market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research's projections on the growth prospects of the oncology mice models market more accurate and reliable

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions & Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Oncology Drugs - Pipeline Analysis
    • 4.1.1. By Intervention
    • 4.1.2. By Phase
    • 4.1.3. By Funding Authority
  • 4.2. Immuno-Oncology Drugs - Pipeline Analysis
    • 4.2.1. By Phase
    • 4.2.2. By Funding Authority
  • 4.3. List of Pharma Companies That Have Ongoing Immuno-Oncology Clinical Trials
  • 4.4. List of Academic & Research Institutes Involved In Ongoing Immuno-Oncology Clinical Trials
  • 4.5. List of Preclinical CROs
  • 4.6. Parent Market Analysis
  • 4.7. Relative Number of Combination Oncology Therapy Trials
  • 4.8. Landscape of Immuno-Oncology Drug Development
  • 4.9. List of Preclinical immuno-oncology models
    • 4.9.1. Cell lines
    • 4.9.2. Mice Models
    • 4.9.3. Organoids/ spheroids
  • 4.10. Key Regulatory Scenario
  • 4.11. Porter's Analysis
  • 4.12. PESTLE Analysis
  • 4.13. Supply Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Covid-19 Pandemic
    • 5.2.2. Prevalence of cancer
    • 5.2.3. Rise in R&D investments
    • 5.2.4. Stringent Regulations
    • 5.2.5. Rise in number of pre-clinical and clinical studies
    • 5.2.6. Increasing investment in Cancer research
    • 5.2.7. GDP Growth
    • 5.2.8. Advancements in Models
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis

  • 6.1. Current COVID19 Statistics and Probable Future Impact
  • 6.2. Current GDP Projection and Probable Impact
  • 6.3. Current Economic Projection as compared to 2008 Economic analysis
  • 6.4. COVID19 and Impact Analysis
  • 6.5. Recovery Scenario - Short term, Midterm, and Long Term Impact

7. Global Oncology Mice Models Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2017- 2021
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032, by Product

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Product, 2017-2021
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2032
    • 8.3.1. Humanized Immune System Mice Models
    • 8.3.2. Syngeneic Tumor Mice Models
    • 8.3.3. Immunodeficient Mice Models
    • 8.3.4. NOG Mice Models
    • 8.3.5. Spontaneous Tumor Mice Models
    • 8.3.6. Others
  • 8.4. Market Attractiveness Analysis By Product

9. Global Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032, by End User

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By End User, 2017-2021
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022-2032
    • 9.3.1. Contract Research Organizations
    • 9.3.2. Pharma and Biopharma Companies
    • 9.3.3. Academic and Research Institutes
  • 9.4. Market Attractiveness Analysis By Indication

10. Global Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032, by Region

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017-2021
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2032
    • 10.3.1. The North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. Asia Pacific
    • 10.3.5. Middle East and Africa (MEA)
  • 10.4 Market Attractiveness Analysis

11. North America Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
  • 11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
    • 11.3.1. By Country
    • 11.3.2. By Product
    • 11.3.3. By End User
  • 11.4. Market Attractiveness Analysis
  • 11.5. Key Market Participants - Intensity Mapping
  • 11.6. Drivers and Restraints - Impact Analysis

12. Latin America Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032

  • 12.1. Introduction / Key Findings
  • 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
  • 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
    • 12.3.1. By Country
    • 12.3.2. By Product
    • 12.3.3. By End User
  • 12.4. Market Attractiveness Analysis
  • 12.5. Key Market Participants - Intensity Mapping
  • 12.6. Drivers and Restraints - Impact Analysis

13. Europe Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032

  • 13.1. Introduction / Key Findings
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
  • 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
    • 13.3.1. By Country
    • 13.3.2. By Product
    • 13.3.3. By End User
  • 13.4. Market Attractiveness Analysis
  • 13.5. Key Market Participants - Intensity Mapping
  • 13.6. Drivers and Restraints - Impact Analysis

14. Asia Pacific Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032

  • 14.1. Introduction / Key Findings
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
  • 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
    • 14.3.1. By Country
    • 14.3.2. By Product
    • 14.3.3. By End User
  • 14.4. Market Attractiveness Analysis
  • 14.5. Key Market Participants - Intensity Mapping
  • 14.6. Drivers and Restraints - Impact Analysis

15. Middle East and Africa (MEA) Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032

  • 15.1. Introduction / Key Findings
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
  • 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
    • 15.3.1. By Country
    • 15.3.2. By Product
    • 15.3.3. By End User
  • 15.4. Market Attractiveness Analysis
  • 15.5. Key Market Participants - Intensity Mapping
  • 15.6. Drivers and Restraints - Impact Analysis

16. Country Level Medical Cart Market Analysis and Forecast 2022 & 2032

  • 16.1. Introduction
    • 16.1.1. Market Value Proportion Analysis
    • 16.1.2. Global VS. Country Growth Comparison
  • 16.2. U.S. Medical Cart Market Analysis
    • 16.2.1. By Product
    • 16.2.2. By End User
  • 16.3. Canada Medical Cart Market Analysis
    • 16.3.1. By Product
    • 16.3.2. By End User
  • 16.4. Brazil Medical Cart Market Analysis
    • 16.4.1. By Product
    • 16.4.2. By End User
  • 16.5. Argentina Medical Cart Market Analysis
    • 16.5.1. By Product
    • 16.5.2. By End User
  • 16.6. Mexico Medical Cart Market Analysis
    • 16.6.1. By Product
    • 16.6.2. By End User
  • 16.7. Germany Medical Cart Market Analysis
    • 16.7.1. By Product
    • 16.7.2. By End User
  • 16.8. Italy Medical Cart Market Analysis
    • 16.8.1. By Product
    • 16.8.2. By End User
  • 16.9. France Medical Cart Market Analysis
    • 16.9.1. By Product
    • 16.9.2. By End User
  • 16.10. U.K. Medical Cart Market Analysis
    • 16.10.1. By Product
    • 16.10.2. By End User
  • 16.11. Spain Medical Cart Market Analysis
    • 16.11.1. By Product
    • 16.11.2. By End User
  • 16.12. BENELUX Medical Cart Market Analysis
    • 16.12.1. By Product
    • 16.12.2. By End User
  • 16.13. Russia Medical Cart Market Analysis
    • 16.13.1. By Product
    • 16.13.2. By End User
  • 16.14. China Medical Cart Market Analysis
    • 16.14.1. By Product
    • 16.14.2. By End User
  • 16.15. Japan Medical Cart Market Analysis
    • 16.15.1. By Product
    • 16.15.2. By End User
  • 16.16. India Medical Cart Market Analysis
    • 16.16.1. By Product
    • 16.16.2. By End User
  • 16.17. Australia and New Zealand Medical Cart Market Analysis
    • 16.17.1. By Product
    • 16.17.2. By End User
  • 16.18. GCC Countries Medical Cart Market Analysis
    • 16.18.1. By Product
    • 16.18.2. By End User
  • 16.19. South Africa Medical Cart Market Analysis
    • 16.19.1. By Product
    • 16.19.2. By End User

17. Market Structure Analysis

  • 17.1. Market Analysis by Tier of Companies
  • 17.2. Market Share Analysis of Top Players

18. Competition Analysis

  • 18.1. Competition Benchmarking
  • 18.2. Competition Dashboard
  • 18.3. Competition Deep Dive
    • 18.3.1. The Jackson Laboratory
      • 18.3.1.1. Overview
      • 18.3.1.2. Product Portfolio
      • 18.3.1.3. Key Financials
      • 18.3.1.4. SWOT Analysis
      • 18.3.1.5. Sales Footprint
      • 18.3.1.6. Strategy Overview
        • 18.3.1.6.1. Marketing Strategy
        • 18.3.1.6.2. Product Strategy
        • 18.3.1.6.3. Channel Strategy
    • 18.3.2. Taconic Biosciences
      • 18.3.2.1. Overview
      • 18.3.2.2. Product Portfolio
      • 18.3.2.3. Key Financials
      • 18.3.2.4. SWOT Analysis
      • 18.3.2.5. Sales Footprint
      • 18.3.2.6. Strategy Overview
        • 18.3.2.6.1. Marketing Strategy
        • 18.3.2.6.2. Product Strategy
        • 18.3.2.6.3. Channel Strategy
    • 18.3.3. Charles River Laboratories
      • 18.3.3.1. Overview
      • 18.3.3.2. Product Portfolio
      • 18.3.3.3. Key Financials
      • 18.3.3.4. SWOT Analysis
      • 18.3.3.5. Sales Footprint
      • 18.3.3.6. Strategy Overview
        • 18.3.3.6.1. Marketing Strategy
        • 18.3.3.6.2. Product Strategy
        • 18.3.3.6.3. Channel Strategy
    • 18.3.4. Shanghai Model Organisms Center Inc.
      • 18.3.4.1. Overview
      • 18.3.4.2. Product Portfolio
      • 18.3.4.3. Key Financials
      • 18.3.4.4. SWOT Analysis
      • 18.3.4.5. Sales Footprint
      • 18.3.4.6. Strategy Overview
        • 18.3.4.6.1. Marketing Strategy
        • 18.3.4.6.2. Product Strategy
        • 18.3.4.6.3. Channel Strategy
    • 18.3.5. Envigo
      • 18.3.5.1. Overview
      • 18.3.5.2. Product Portfolio
      • 18.3.5.3. Key Financials
      • 18.3.5.4. SWOT Analysis
      • 18.3.5.5. Sales Footprint
      • 18.3.5.6. Strategy Overview
        • 18.3.5.6.1. Marketing Strategy
        • 18.3.5.6.2. Product Strategy
        • 18.3.5.6.3. Channel Strategy
    • 18.3.6. Biocytogen
      • 18.3.6.1. Overview
      • 18.3.6.2. Product Portfolio
      • 18.3.6.3. Key Financials
      • 18.3.6.4. SWOT Analysis
      • 18.3.6.5. Sales Footprint
      • 18.3.6.6. Strategy Overview
        • 18.3.6.6.1. Marketing Strategy
        • 18.3.6.6.2. Product Strategy
        • 18.3.6.6.3. Channel Strategy
    • 18.3.7. Genoway
      • 18.3.7.1. Overview
      • 18.3.7.2. Product Portfolio
      • 18.3.7.3. Key Financials
      • 18.3.7.4. SWOT Analysis
      • 18.3.7.5. Sales Footprint
      • 18.3.7.6. Strategy Overview
        • 18.3.7.6.1. Marketing Strategy
        • 18.3.7.6.2. Product Strategy
        • 18.3.7.6.3. Channel Strategy
    • 18.3.8. Crown Bioscience Inc. (JSR Corporation).
      • 18.3.8.1. Overview
      • 18.3.8.2. Product Portfolio
      • 18.3.8.3. Key Financials
      • 18.3.8.4. SWOT Analysis
      • 18.3.8.5. Sales Footprint
      • 18.3.8.6. Strategy Overview
        • 18.3.8.6.1. Marketing Strategy
        • 18.3.8.6.2. Product Strategy
        • 18.3.8.6.3. Channel Strategy
    • 18.3.9. Cyagen
      • 18.3.9.1. Overview
      • 18.3.9.2. Product Portfolio
      • 18.3.9.3. Key Financials
      • 18.3.9.4. SWOT Analysis
      • 18.3.9.5. Sales Footprint
      • 18.3.9.6. Strategy Overview
        • 18.3.9.6.1. Marketing Strategy
        • 18.3.9.6.2. Product Strategy
        • 18.3.9.6.3. Channel Strategy
    • 18.3.10. Applied stem cells
      • 18.3.10.1. Overview
      • 18.3.10.2. Product Portfolio
      • 18.3.10.3. Key Financials
      • 18.3.10.4. SWOT Analysis
      • 18.3.10.5. Sales Footprint
      • 18.3.10.6. Strategy Overview
        • 18.3.10.6.1. Marketing Strategy
        • 18.3.10.6.2. Product Strategy
        • 18.3.10.6.3. Channel Strategy
    • 18.3.11. Ingenious Targeting Laboratory
      • 18.3.11.1. Overview
      • 18.3.11.2. Product Portfolio
      • 18.3.11.3. Key Financials
      • 18.3.11.4. SWOT Analysis
      • 18.3.11.5. Sales Footprint
      • 18.3.11.6. Strategy Overview
        • 18.3.11.6.1. Marketing Strategy
        • 18.3.11.6.2. Product Strategy
        • 18.3.11.6.3. Channel Strategy
    • 18.3.12. PolyGene - Transgenic mice model company
      • 18.3.12.1. Overview
      • 18.3.12.2. Product Portfolio
      • 18.3.12.3. Key Financials
      • 18.3.12.4. SWOT Analysis
      • 18.3.12.5. Sales Footprint
      • 18.3.12.6. Strategy Overview
        • 18.3.12.6.1. Marketing Strategy
        • 18.3.12.6.2. Product Strategy
        • 18.3.12.6.3. Channel Strategy
    • 18.3.13. Creative Biolabs
      • 18.3.13.1. Overview
      • 18.3.13.2. Product Portfolio
      • 18.3.13.3. Key Financials
      • 18.3.13.4. SWOT Analysis
      • 18.3.13.5. Sales Footprint
      • 18.3.13.6. Strategy Overview
        • 18.3.13.6.1. Marketing Strategy
        • 18.3.13.6.2. Product Strategy
        • 18.3.13.6.3. Channel Strategy
    • 18.3.14. TransCure Bioservices
      • 18.3.14.1. Overview
      • 18.3.14.2. Product Portfolio
      • 18.3.14.3. Key Financials
      • 18.3.14.4. SWOT Analysis
      • 18.3.14.5. Sales Footprint
      • 18.3.14.6. Strategy Overview
        • 18.3.14.6.1. Marketing Strategy
        • 18.3.14.6.2. Product Strategy
        • 18.3.14.6.3. Channel Strategy
    • 18.3.15. Champions Oncology Inc
      • 18.3.15.1. Overview
      • 18.3.15.2. Product Portfolio
      • 18.3.15.3. Key Financials
      • 18.3.15.4. SWOT Analysis
      • 18.3.15.5. Sales Footprint
      • 18.3.15.6. Strategy Overview
        • 18.3.15.6.1. Marketing Strategy
        • 18.3.15.6.2. Product Strategy
        • 18.3.15.6.3. Channel Strategy
    • 18.3.16. Certis Oncology
      • 18.3.16.1. Overview
      • 18.3.16.2. Product Portfolio
      • 18.3.16.3. Key Financials
      • 18.3.16.4. SWOT Analysis
      • 18.3.16.5. Sales Footprint
      • 18.3.16.6. Strategy Overview
        • 18.3.16.6.1. Marketing Strategy
        • 18.3.16.6.2. Product Strategy
        • 18.3.16.6.3. Channel Strategy
    • 18.3.17. Signature
      • 18.3.17.1. Overview
      • 18.3.17.2. Product Portfolio
      • 18.3.17.3. Key Financials
      • 18.3.17.4. SWOT Analysis
      • 18.3.17.5. Sales Footprint
      • 18.3.17.6. Strategy Overview
        • 18.3.17.6.1. Marketing Strategy
        • 18.3.17.6.2. Product Strategy
        • 18.3.17.6.3. Channel Strategy
    • 18.3.18. Pharmaron
      • 18.3.18.1. Overview
      • 18.3.18.2. Product Portfolio
      • 18.3.18.3. Key Financials
      • 18.3.18.4. SWOT Analysis
      • 18.3.18.5. Sales Footprint
      • 18.3.18.6. Strategy Overview
        • 18.3.18.6.1. Marketing Strategy
        • 18.3.18.6.2. Product Strategy
        • 18.3.18.6.3. Channel Strategy
    • 18.3.19. Laboratory Corporation of America Holdings
      • 18.3.19.1. Overview
      • 18.3.19.2. Product Portfolio
      • 18.3.19.3. Key Financials
      • 18.3.19.4. SWOT Analysis
      • 18.3.19.5. Sales Footprint
      • 18.3.19.6. Strategy Overview
        • 18.3.19.6.1. Marketing Strategy
        • 18.3.19.6.2. Product Strategy
        • 18.3.19.6.3. Channel Strategy
    • 18.3.20. Gempharmatech
      • 18.3.20.1. Overview
      • 18.3.20.2. Product Portfolio
      • 18.3.20.3. Key Financials
      • 18.3.20.4. SWOT Analysis
      • 18.3.20.5. Sales Footprint
      • 18.3.20.6. Strategy Overview
        • 18.3.20.6.1. Marketing Strategy
        • 18.3.20.6.2. Product Strategy
        • 18.3.20.6.3. Channel Strategy
    • 18.3.21. Janvier Labs
      • 18.3.21.1. Overview
      • 18.3.21.2. Product Portfolio
      • 18.3.21.3. Key Financials
      • 18.3.21.4. SWOT Analysis
      • 18.3.21.5. Sales Footprint
      • 18.3.21.6. Strategy Overview
        • 18.3.21.6.1. Marketing Strategy
        • 18.3.21.6.2. Product Strategy
        • 18.3.21.6.3. Channel Strategy
    • 18.3.22. Harbour BioMed
      • 18.3.22.1. Overview
      • 18.3.22.2. Product Portfolio
      • 18.3.22.3. Key Financials
      • 18.3.22.4. SWOT Analysis
      • 18.3.22.5. Sales Footprint
      • 18.3.22.6. Strategy Overview
        • 18.3.22.6.1. Marketing Strategy
        • 18.3.22.6.2. Product Strategy
        • 18.3.22.6.3. Channel Strategy

19. Assumptions and Acronyms Used

20. Research Methodology